FNY Investment Advisers’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

FNY Investment Advisers’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-314	Closed	-$18K	–	640
2020 Q1	$18K	Buy	314 +200	+175%	+$19.6K	0.01%	281
2019 Q4	$14K	Buy	114 +11	+11%	+$1.49K	﹤0.01%	607
2019 Q3	$12K	Buy	103 +94	+1,044%	+$18.9K	﹤0.01%	570
2019 Q2	$2K	Buy	+9	New	+$3.75K	﹤0.01%	850
2018 Q4	–	Sell	-442	Closed	-$402K	–	1124
2018 Q3	$402K	Buy	+442	New	+$292K	0.09%	127

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kalos Management Alpharetta, Georgia $46.6M AUM 11.52% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

FNY Investment Advisers's HTGM Position: Q2 2020 in Review

FNY Investment Advisers sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2020, closing a stake of 314 shares — an estimated $18K sold.

FNY Investment Advisers first reported a position in HTGM in Q3 2018 and held it in 5 quarters. The position peaked at $402K in Q3 2018. 28 funds tracked by Wall St. Rank hold HTGM as of Q2 2020.

FNY Investment Advisers reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
FNY Investment Advisers sold 314 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2020, an estimated $18K.
FNY Investment Advisers first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2018 and held it in 5 quarters.
FNY Investment Advisers's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $402K in Q3 2018.
28 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2020.

Based on FNY Investment Advisers's 13F filing for Q2 2020, filed 10 Jul 2020.